MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to alzheimer’s disease | Center for Neurodegeneration and Translational Neuroscience (CNTN)

Decourt B, Wilson J, Ritter A, Dardis C, Difilippo FP, Zhuang X

Open Access J Clin Trials

January 2020

← Back to Publications